DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible

Phase 3 ALCYONE data showed DARZALEX in combination with bortezomib, melphalan and prednisone meaningfully improved progression-free survival and response rates Data featured as late-breaker at ASH 2017 (Abstract #LBA-4) and published in the New England... Biopharmaceuticals, Oncology Janssen Biotech, DARZALEX, daratumumab, multiple myeloma

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043277

Source: HSMN NewsFeed - December 12, 2017 Category: Pharmaceuticals Source Type: news